CanSino Biologics (HKG:6185, SHA:688185) said its new drug application for tetanus vaccine was accepted by the National Medical Products Administration of China, a Thursday bourse filing said.
Tetanus, a severe infectious disease, is caused by Clostridium tetani with a mortality rate reaching 30%-50% with medical intervention while the rate stands at 100% without medical intervention.
The vaccine, developed by the company, is aimed at non-neonatal tetanus prevention. It is safer as it is fermented with an animal-free culture medium, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.